Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma

Abstract Background Re‐designing services and processes to meet growing demands in chemotherapy services is necessary with increasing treatments. There is little evidence guiding the timing and thresholds to be attained of pre‐chemotherapy blood assessments, namely neutrophils. Methods A survey was...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pinkie Chambers, Li Wei, Martin D. Forster, Emma Kipps, Ian C. K. Wong, Yogini Jani
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	chemotherapy monitoring platelets neutrophils treatment‐delay Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/c2d93df85d484e55825b6620d0560ff8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c2d93df85d484e55825b6620d0560ff8
record_format	dspace
spelling	oai:doaj.org-article:c2d93df85d484e55825b6620d0560ff82021-11-22T09:08:47ZEvidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma2045-763410.1002/cam4.4316https://doaj.org/article/c2d93df85d484e55825b6620d0560ff82021-11-01T00:00:00Zhttps://doi.org/10.1002/cam4.4316https://doaj.org/toc/2045-7634Abstract Background Re‐designing services and processes to meet growing demands in chemotherapy services is necessary with increasing treatments. There is little evidence guiding the timing and thresholds to be attained of pre‐chemotherapy blood assessments, namely neutrophils. Methods A survey was developed and distributed to health professionals in the United Kingdom (UK) to examine current practice in timing and threshold values of neutrophils and platelets before treatment administration. This was followed by a retrospective cohort study, using data from electronic patient record systems; including patients initiating treatment between January 2013 and December 2018, to determine a safe timeframe for blood assessments; comparing neutrophil, platelet, creatinine and bilirubin levels at different time points. Results The survey captured 25% of hospitals in the UK and variations were apparent in both the timing of assessments and thresholds needed, particularly for neutrophils. 616 (6.5%) of 4007 patients included had neutrophil levels measured twice within 7 days of treatment (with the first level taken beyond 3 days and the second test being within 3 days of treatment‐ the UK standard). Of the patients that attained an acceptable neutrophil level at their first test, five of the 616 (0.8%) became ineligible for administration from the test 2 level. 23% of patients improved their grade and became eligible for treatment. Little difference was observed for platelets. Conclusions We have demonstrated that extending the timeframe for blood tests can be safe, however, this practice may cause unnecessary delays for patients if only an early test is relied on for eligibility.Pinkie ChambersLi WeiMartin D. ForsterEmma KippsIan C. K. WongYogini JaniWileyarticlechemotherapymonitoringplateletsneutrophilstreatment‐delayNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 22, Pp 7996-8004 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	chemotherapy monitoring platelets neutrophils treatment‐delay Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	chemotherapy monitoring platelets neutrophils treatment‐delay Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Pinkie Chambers Li Wei Martin D. Forster Emma Kipps Ian C. K. Wong Yogini Jani Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
description	Abstract Background Re‐designing services and processes to meet growing demands in chemotherapy services is necessary with increasing treatments. There is little evidence guiding the timing and thresholds to be attained of pre‐chemotherapy blood assessments, namely neutrophils. Methods A survey was developed and distributed to health professionals in the United Kingdom (UK) to examine current practice in timing and threshold values of neutrophils and platelets before treatment administration. This was followed by a retrospective cohort study, using data from electronic patient record systems; including patients initiating treatment between January 2013 and December 2018, to determine a safe timeframe for blood assessments; comparing neutrophil, platelet, creatinine and bilirubin levels at different time points. Results The survey captured 25% of hospitals in the UK and variations were apparent in both the timing of assessments and thresholds needed, particularly for neutrophils. 616 (6.5%) of 4007 patients included had neutrophil levels measured twice within 7 days of treatment (with the first level taken beyond 3 days and the second test being within 3 days of treatment‐ the UK standard). Of the patients that attained an acceptable neutrophil level at their first test, five of the 616 (0.8%) became ineligible for administration from the test 2 level. 23% of patients improved their grade and became eligible for treatment. Little difference was observed for platelets. Conclusions We have demonstrated that extending the timeframe for blood tests can be safe, however, this practice may cause unnecessary delays for patients if only an early test is relied on for eligibility.
format	article
author	Pinkie Chambers Li Wei Martin D. Forster Emma Kipps Ian C. K. Wong Yogini Jani
author_facet	Pinkie Chambers Li Wei Martin D. Forster Emma Kipps Ian C. K. Wong Yogini Jani
author_sort	Pinkie Chambers
title	Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
title_short	Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
title_full	Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
title_fullStr	Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
title_full_unstemmed	Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma
title_sort	evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large b‐cell lymphoma
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/c2d93df85d484e55825b6620d0560ff8
work_keys_str_mv	AT pinkiechambers evidencetoguidetheoptimaltimingforprechemotherapybloodtestsforearlybreastcolorectalcanceranddiffuselargebcelllymphoma AT liwei evidencetoguidetheoptimaltimingforprechemotherapybloodtestsforearlybreastcolorectalcanceranddiffuselargebcelllymphoma AT martindforster evidencetoguidetheoptimaltimingforprechemotherapybloodtestsforearlybreastcolorectalcanceranddiffuselargebcelllymphoma AT emmakipps evidencetoguidetheoptimaltimingforprechemotherapybloodtestsforearlybreastcolorectalcanceranddiffuselargebcelllymphoma AT ianckwong evidencetoguidetheoptimaltimingforprechemotherapybloodtestsforearlybreastcolorectalcanceranddiffuselargebcelllymphoma AT yoginijani evidencetoguidetheoptimaltimingforprechemotherapybloodtestsforearlybreastcolorectalcanceranddiffuselargebcelllymphoma
_version_	1718417818978877440

Evidence to guide the optimal timing for pre‐chemotherapy blood tests for early breast, colorectal cancer and diffuse large B‐cell lymphoma

Ejemplares similares